Michael Mullan
17Patents
4h-index
13Co-inventors
57Inventor score
Filing activity: Jan 21, 1992 → Sep 2, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5455169A | Nucleic acids for diagnosing and modeling Alzheimer's disease | Chemistry; Metallurgy | 80 | Expired |
| US5877015A | APP770 mutant in alzheimer's disease | Chemistry; Metallurgy | 78 | Expired |
| US5795963A | Amyloid precursor protein in alzheimer's disease | Chemistry; Metallurgy | 38 | Expired |
| US7589168B2 | Inhibition of angiogenesis by A-β peptides | Physics | 4 | Expired |
| US6011019A | Vasoactive effects and free radical generation by .beta.-amyloid peptides | Human Necessities | 4 | Expired |
| US7052852B1 | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease | Physics | 4 | Expired |
| US6818448B2 | Isolated cell comprising HAPP 670/671 DNAS sequences | Chemistry; Metallurgy | 3 | Expired |
| US8067372B2 | Modulation of angiogenesis by A-beta peptide fragments | Human Necessities | 2 | Active |
| US6787318B1 | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology | Emerging Cross-Sectional Technologies | 2 | Expired |
| US6140309A | Vasoactive effects and free radical generation by .beta.-amyloid peptides | Human Necessities | 2 | Expired |
| US7538258B2 | Transgenic mouse expressing an APP 670/671 mutation | Chemistry; Metallurgy | 2 | Active |
| US6300540A | Transgenic mouse expressing an APP-FAD DNA sequence | Chemistry; Metallurgy | 1 | Expired |
| US8236346B2 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer | Human Necessities | 0 | Active |
| US11865107B2 | Pharmaceutical composition | Human Necessities | 0 | Active |
| US7732467B2 | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis | Human Necessities | 0 | Active |
| US8236347B2 | Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis | Human Necessities | 0 | Active |
| US7605149B1 | Modulation of the phospholipase A2 pathway as a therapeutic | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.